Evidence map›Paper›PMID 28482102›Full record

ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2017

Apolipoprotein E4 Allele and Gait Performance in Mild Cognitive Impairment: Results From the Gait and Brain Study.

Ryota Sakurai, Manuel Montero-Odasso

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03020381 (Gait as Predictor of Cognitive Decline, Dementia, and Risk of Falls in MCI. A Cohort Study), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03020381 recruitingnot on this map

Gait as Predictor of Cognitive Decline, Dementia, and Risk of Falls in MCI. A Cohort Study

TypeobservationalSponsorManuel Montero OdassoRan2007 to 2033Enrolled600ConditionsGait Apraxia, Mild Cognitive Impairment, Subjective Cognitive Impairment, Cerebral Atrophy
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Three Doses of Vitamin D and Cognitive Outcomes in Older Women: A Double-Blind Randomized Controlled Trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020
    Trial
  3. Observational
  4. Falls predict faster progression to Alzheimer's dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. Exploratory associations between APOE-εFrontiers in neurology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Link among apolipoprotein E E4, gait, and cognition in neurodegenerative diseases: ONDRI study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ryota SakuraiGait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Canada.
Manuel Montero-OdassoGait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe apolipoprotein E polymorphism ε4 allele (ApoE4) and gait impairment are both known risk factors for developing cognitive decline and dementia. However, it is unclear the interrelationship between these factors, particularly among older adults with mild cognitive impairment (MCI) who are considered as prodromal for Alzheimer's disease. This study aimed to determine whether ApoE4 carrier individuals with MCI may experience greater impairment in gait performance.

methodsFifty-six older adults with MCI from the "Gait and Brain Study" who were identified as either ApoE4 carriers (n = 20) or non-ApoE4 carriers (n = 36) with 1 year of follow-up were included. Gait variability, the main outcome variable, was assessed as stride time variability with an electronic walkway. Additional gait variables and cognitive performance (mini-mental state examination [MMSE] and Montreal Cognitive Assessment [MoCA]) were also recorded. Covariates included age, sex, education level, body mass index, and number of comorbidities.

resultsBaseline characteristics were similar for both groups. Repeated measures analysis of covariance showed that gait stride time and stride length variabilities significantly increased in ApoE4 carriers but was maintained in the non-ApoE4 carriers. Similarly, ApoE4 carriers showed greater decrease in MMSE score at follow-up.

conclusionsIn this sample of older adults with MCI, the presence of at least one copy of ApoE4 was associated with the development of both increased gait variability and cognitive decline during 1 year of follow-up. ApoE4 genotype might be considered as a potential mediator of decline in mobility function in MCI; future studies with larger samples are needed to confirm our preliminary findings.

Indexed as

AllelesAgedApolipoprotein E4Cognitive DysfunctionFemaleGaitHumansLongitudinal StudiesMaleProspective StudiesApolipoprotein E4Apolipoprotein ECognitionGait variabilityLongitudinal studyMild cognitive impairment

Identifiers

PMID28482102
PMCPMC5861852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.